CKD, also known as chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. As the disease progresses, the symptoms worsen, eventually leading to kidney failure. The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.
In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of CKD, stages I–V, will grow by 9.9% over the forecast period, at an Annual Growth Rate (AGR) of 0.99%, from 25,777,808 cases in 2016 to 28,329,633 cases in 2026. In 2016, the US accounted for 21.56% of the diagnosed prevalent cases of CKD in the 7MM, with 5,557,199 cases. There were 17,187,838 cases in the 5EU, with 66.68% of the diagnosed prevalent cases. Japan had 3,032,771 cases, accounting for 11.77% of the diagnosed prevalent cases in the 7MM in 2016. Of the 7MM, the UK is expected to have the highest number of diagnosed prevalent cases, increasing from 13,397,021 in 2016 to 14,035,651 in 2026.
Details about the trend analysis and other discussions of CKD epidemiology can be found in the EpiCast Report: Chronic Kidney Disease – Epidemiology Forecast to 2026 and the EpiCast Model: Chronic Kidney Disease – Epidemiology Forecast to 2026.